AI eye scanner could catch dry AMD early in 1,000-Person trial
NCT ID NCT07446582
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study is testing whether an AI system called DeepMSI AI can detect biomarkers of dry age-related macular degeneration (AMD) as accurately as experienced eye doctors. About 1,000 adults over 40, including those with and without AMD, will have their retinas imaged with a special camera. The AI's analysis will be compared to the judgment of retina specialists to see if the technology is reliable enough for future use.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Retina imaging device (MSI-120) and AI software (DeepMSI AI)
- What this could lead to
- If successful, this could provide a fast, AI-powered way to detect early signs of dry age-related macular degeneration, potentially improving diagnosis and monitoring.
- What could go wrong
- This is an early-stage study focused on accuracy, not treatment. The AI results are not shared with doctors during the trial, so there is no direct benefit to participants. The technology may not prove equivalent to human experts.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AGE-RELATED (DRY) MACULAR DEGENERATION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Contact Lens & Vision
RECRUITINGWoodbridge, New Jersey, 07095, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.